Liege, Belgium - Mithra (Euronext Brussels: MITRA), a company dedicated to women s health, announces today that it has been granted two additional patents for NEXTSTELLIS (3 mg drospirenone and 14.2 mg estetrol (E4) tablets) in the United States.

The U.S. patent numbers are 11,957,694 and 11,964,055.

The patents, which are FDA Orange Book1 listed, provide additional protection to the NEXTSTELLIS formulation. Both newly listed patents are terminally disclaimed over the previously announced U.S. Patent No. 11,793,760 (listed in October 2023) and will also expire on 17 June 2036.

NEXTSTELLIS is the first and only contraceptive pill featuring the new estrogen E4, in combination with the well-established progestin drospirenone. E4 is a native and tissue selective estrogen with distinct effects on breast tissues and the liver. Notably, E4 is naturally produced by the human fetus during pregnancy. The E4 in NEXTSTELLIS is produced from a plant source.

Mithra s commercialization partner, Mayne Pharma Group Limited (ASX: MYX), holds the license and supply agreement for NEXTSTELLIS/ESTELLE in the United States since 2021.

Graham Dixon, Chief Scientific Officer of Mithra, stated, We are excited to have been granted additional patent coverage for ESTELLE under the trademark NEXTSTELLIS, an oral contraceptive with a novel estrogen, in the United States. The new patents complement our previous patent (11,793,760) by offering different or additional scopes of claims to enforce our patent rights. We currently have several additional patent applications pending, demonstrating our ongoing commitment to patent-protect our breakthrough innovations.

Contact:

Tel: +32 (0)4 349 28 22

Email: info@mithra.com

Tel: +32 (0)4 353 37 00

Email: info@mithracdmo.com

(C) 2024 Electronic News Publishing, source ENP Newswire